Defects in platelet adhesion and aggregate formation in uremic bleeding disorder can be attributed to factors in plasma
- PMID: 2029508
- DOI: 10.1161/01.atv.11.3.733
Defects in platelet adhesion and aggregate formation in uremic bleeding disorder can be attributed to factors in plasma
Abstract
Uremia is associated with bleeding diathesis. Platelet adhesion to the subendothelium is inhibited by a factor in uremic plasma that may play a role in the disturbed hemostasis of uremic patients. In the formation of the hemostatic plug, platelet adherence is followed by stimulus-induced platelet aggregation and reinforcement by thrombin-generated fibrin. To study these processes in uremic blood, a newly developed thrombosis model was used. Perfusates anticoagulated with low-molecular-weight heparin were circulated over a matrix of stimulated cultured endothelial cells. By stimulation of the endothelial cells, tissue factor was synthesized and deposited in the matrix. When this tissue factor rich-matrix was exposed to flowing blood, local thrombin was formed via activation of the extrinsic coagulation pathway. With this system, platelet adhesion, thrombin-dependent platelet activation, and fibrin formation can all be studied at the same surface. In addition to an adhesion defect, decreased aggregate formation was also found in uremic perfusates. Normal platelets in uremic plasma showed similar results, which indicates that a factor in uremic plasma caused this adhesion and aggregation defect. Platelet aggregation in the system was dependent on endogenously formed thrombin. Fibrinopeptide A generation, however, was normal in uremic perfusates; therefore, uremic plasma has a normal capacity to form thrombin. Resuspension of washed uremic platelets in control plasma did not reverse the aggregation defect in perfusions. In contrast, aggregometer studies with isolated uremic platelets could not detect an abnormal response to threshold concentrations of exogenous thrombin. Thus, uremic toxin(s) cause defective aggregate formation in flow, but not necessarily in the aggregometer. This apparent discrepancy may be due to the higher shear forces in the flow system, which may prevent aggregate formation that is allowed in the aggregometer. Another explanation, that uremic platelets are less responsive to locally formed thrombin than they are to exogenously added thrombin, seems less likely.
Similar articles
-
Treatment of uremic anemia with recombinant erythropoietin also reduces the defects in platelet adhesion and aggregation caused by uremic plasma.Thromb Haemost. 1991 Dec 2;66(6):638-47. Thromb Haemost. 1991. PMID: 1665596 Clinical Trial.
-
Activation of endothelial cells induces platelet thrombus formation on their matrix. Studies of new in vitro thrombosis model with low molecular weight heparin as anticoagulant.Arteriosclerosis. 1990 Jan-Feb;10(1):49-61. doi: 10.1161/01.atv.10.1.49. Arteriosclerosis. 1990. PMID: 2297347
-
Defective platelet adhesion on vessel subendothelium in uremic patients.Blood. 1986 Aug;68(2):337-42. Blood. 1986. PMID: 3730605
-
Disorders of platelet function.Dis Mon. 1992 Aug;38(8):577-631. Dis Mon. 1992. PMID: 1321709 Review.
-
Platelets and their membranes in hemostasis: physiology and pathophysiology.Ann Intern Med. 1981 Jan;94(1):108-18. doi: 10.7326/0003-4819-94-1-108. Ann Intern Med. 1981. PMID: 7004296 Review.
Cited by
-
A hypothesis-generating study to evaluate platelet activity in diabetics with chronic kidney disease.Thromb J. 2005 Mar 29;3(1):3. doi: 10.1186/1477-9560-3-3. Thromb J. 2005. PMID: 15796773 Free PMC article.
-
Evaluation of hemostasis in patients with end-stage renal disease.PLoS One. 2019 Feb 20;14(2):e0212237. doi: 10.1371/journal.pone.0212237. eCollection 2019. PLoS One. 2019. PMID: 30785941 Free PMC article. Clinical Trial.
-
Whole blood platelet aggregation and release reaction testing in uremic patients.Biomed Res Int. 2013;2013:486290. doi: 10.1155/2013/486290. Epub 2013 Jun 26. Biomed Res Int. 2013. PMID: 23878808 Free PMC article.
-
Abnormal cytoskeletal assembly in platelets from uremic patients.Am J Pathol. 1993 Sep;143(3):823-31. Am J Pathol. 1993. PMID: 8362980 Free PMC article.
-
Antiplatelet agents for chronic kidney disease.Cochrane Database Syst Rev. 2022 Feb 28;2(2):CD008834. doi: 10.1002/14651858.CD008834.pub4. Cochrane Database Syst Rev. 2022. PMID: 35224730 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical